
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Alexander Kantorovich, PharmD, BCPS, clinical assistant professor of pharmacy practice at Chicago State University College of Pharmacy, discusses how a patient's renal function affects appropriate dosing of new oral anticoagulants.
Alexander Kantorovich, PharmD, BCPS, clinical assistant professor of pharmacy practice at Chicago State University College of Pharmacy, discusses how a patient’s renal function affects appropriate dosing of new oral anticoagulants.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.






